生殖器高危HPV感染及防治现状
|
摘要
人乳头瘤病毒(HPV)感染是最常见的性传播疾病之一,长期持续的高危HPV感染常与生殖器肿瘤密切相关,因此治疗上应适度干预、密切随访,阻断或延缓其病程进展。目前生殖器高危HPV感染的治疗方法主要可分为传统治疗(如冷冻、激光)及新兴治疗(光动力治疗)两类,同时HPV疫苗的出现为生殖器高危HPV的生物学预防带来了新方法,本文就不同治疗方法的特点及疫苗相关问题进行简要概述。
Human papilloma virus(HPV)infection is the most common sexually transmitted disease in the world.Long-term and continuous high-risk HPV infection is closely linked to genital cancers,so appropriate intervention should be carried out in the treatment and with close follow-up to block or delay the progress of the disease course.This review aims to summarize the normal treatment such as cryotherapy,photodynamic therapy,which is more efficient in eliminating and reducing HPV to undetectable levels.HPV vaccines can also prevent some of the most common types of the infection effectively.
Human papilloma virus(HPV)infection is the most common sexually transmitted disease in the world.Long-term and continuous high-risk HPV infection is closely linked to genital cancers,so appropriate intervention should be carried out in the treatment and with close follow-up to block or delay the progress of the disease course.This review aims to summarize the normal treatment such as cryotherapy,photodynamic therapy,which is more efficient in eliminating and reducing HPV to undetectable levels.HPV vaccines can also prevent some of the most common types of the infection effectively.
引文
[1]Santos Filho MV,Gurgel AP,Lobo CD,et al.Prevalence of human papillomavirus(HPV),distribution of HPV types,and risk factors for infection in HPV-positive women[J].Genetics and molecular research:GMR,2016,15(2):1-8.
[2]Cates W.Estimates of the incidence and prevalence of sexually transmitted diseases in the United States American Social Health Association Panel[J].Sexually transmitted diseases,1999,26(4Suppl):S2-7.
[3]Han JJ,Beltran TH,Song JW,et al.Prevalence of Genital Human Papillomavirus Infection and Human Papillomavirus Vaccination Rates Among US Adult Men:National Health and Nutrition Examination Survey(NHANES)2013-2014[J].JAMA oncology,2017,3(6):810-816.
[4]Lopez-Diez E,Perez S,Carballo M,et al.Lifestyle factors and oncogenic papillomavirus infection in a high-risk male population[J].PLoS One,2017,12(9):e0184492.
[5]Teixeira LO,Amaral SC,Finger-Jardim F,et al.Frequency of Human Papillomavirus in the placenta,in the colostrum and in the umbilical cord blood[J].Revista brasileira de ginecologia e obstetrícia:revista da Federac2o Brasileira das Sociedades de Ginecologia e Obstetrícia,2015,37(5):203-207.
[6]Sinclair KA,Woods CR.Venereal warts in children[J].Pediatrics in review/American Academy of Pediatrics,2011,32(3):115-121.
[7]Quint KD,de Koning MN,Quint WG.Progression of cervical low grade squamous intraepithelial lesions:in search of prognostic biomarkers[J].European journal of obstetrics,gynecology,and reproductive biology,2013,170(2):501-506.
[8]Chin-Hong PV,Vittinghoff E,Cranston RD,et al.Age-related prevalence of anal cancer precursors in homosexual men:the EX-PLORE study[J].Journal of the National Cancer Institute,2005,97(12):896-905.
[9]de Sanjose S,Quint WG,Alemany L,et al.Human papillomavirus genotype attribution in invasive cervical cancer:a retrospective cross-sectional worldwide study[J].The Lancet.Oncology,2010,11(11):1048-1056.
[10]Alemany L,Cubilla A,Halec G,et al.Role of Human Papillomavirus in Penile Carcinomas Worldwide[J].European urology,2016,69(5):953-961.
[11]Richardson H,Kelsall G,Tellier P,et al.The natural history of type-specific human papillomavirus infections in female university students[J].Cancer epidemiology,biomarkers&prevention:apublication of the American Association for Cancer Research,cosponsored by the American Society of Preventive Oncology,2003,12(6):485-490.
[12]王秀丽,徐世正,张春荣,等.δ-氨基酮戊酸光动力疗法治疗男性尿道尖锐湿疣[J].中国皮肤性病学杂志,2001,15(2):103-104.
[13]Du J,Lu XN,Li F,et al.Comparison between photodynamic therapy with topical application of 5-aminolevulinic acid and CO2laser therapy in the treatment of cervical condylomata acuminate:a randomized controlled trial[J].International journal of clinical and experimental,2015,8(7):11342-11346.
[14]Shi H,Zhang X,Ma C,et al.Clinical analysis of five methods used to treat condylomata acuminata[J].Dermatology(Basel,Switzerland),2013,227(4):338-345.
[15]王秀丽,姚红霞,缪飞,等.5-氨基酮戊酸光动力疗法治疗宫颈上皮内瘤样病变Ⅰ级[J].中华临床医师杂志(电子版),2011,5(16):4751-4755.
[16]Schiller JT,CastellsaguéX.A review of clinical trials of human papillomavirus prophylactic vaccines[J].Vaccine,2012,30Suppl(5):F123-138.
[17]Kann L,McManus T,Harris WA,et al.Youth Risk Behavior Surveillance-United States,2015[J].Morbidity and mortality weekly report.Surveillance summaries(Washington,D.C.:2002),2016,65(6):1-174.
[18]Schwarz T,Spaczynski M,Kaufmann A,et al.Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55years and first-time modelling of antibody responses in mature women:results from an open-label 6-year follow-up study[J].BJOG:an international journal of obstetrics and gynaecology,2015,122(1):107-118.
[19]CastellsaguéX,Mu1oz N,Pitisuttithum P,et al.End-of-study safety,immunogenicity,and efficacy of quadrivalent HPV(types 6,11,16,18)recombinant vaccine in adult women 24-45years of age[J].British journal of cancer,2011,105(1):28-37.
[20]Schwarz TF,Spaczynski M,Schneider A,et al.Immunogenicity and tolerability of an HPV-16/18AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55years[J].Vaccine,2009,27(4):581-587.
[21]Dobson SR,McNeil S,Dionne M,et al.Immunogenicity of 2doses of HPV vaccine in younger adolescents vs 3doses in young women:a randomized clinical trial[J].JAMA,2013,309(17):1793-1802.
[22]Petrosky E,Bocchini JA,Hariri S,et al.Use of 9-valent human papillomavirus(HPV)vaccine:updated HPV vaccination recommendations of the advisory committee on immunization practices[J].MMWR,2015,64(11):300-304.
[23]Th9ne K,Horn J.Evaluation of vaccination herd immunity effects for anogenital warts in a low coverage setting with human papillomavirus vaccine-an interrupted time series analysis from2005to 2010using health insurance data[J].BMC infectious diseases,2017,17(1):564.
[24]Garland SM,Ault KA,Gall SA,et al.Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine:a combined analysis of five randomized controlled trials[J].Obstetrics and gynecology,2009,114(6):1179-1188.
[25]Paavonen J,Naud P,Salmerón J,et al.Efficacy of human papillomavirus(HPV)-16/18AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types(PA-TRICIA):final analysis of a double-blind,randomised study in young women[J].Lancet,2009,374(9686):301-314.
[26]Bednarczyk RA,Davis R,Ault K,et al.Sexual activity-related outcomes after human papillomavirus vaccination of 11-to 12-year-olds[J].Pediatrics,2012,130(5):798-805.
[27]Ferris D,Samakoses R,Block SL,et al.Long-term study of a quadrivalent human papillomavirus vaccine[J].Pediatrics,2014,134(3):e657-665.
[28]Werner RN,Westfechtel L,Dressler C.Anogenital warts and other HPV-associated anogenital lesions in the HIV-positive patient:a systematic review and meta-analysis of the efficacy and safety of interventions assessed in controlled clinical trials[J].Sexually transmitted infections,2017,93(8):543-550.
[2]Cates W.Estimates of the incidence and prevalence of sexually transmitted diseases in the United States American Social Health Association Panel[J].Sexually transmitted diseases,1999,26(4Suppl):S2-7.
[3]Han JJ,Beltran TH,Song JW,et al.Prevalence of Genital Human Papillomavirus Infection and Human Papillomavirus Vaccination Rates Among US Adult Men:National Health and Nutrition Examination Survey(NHANES)2013-2014[J].JAMA oncology,2017,3(6):810-816.
[4]Lopez-Diez E,Perez S,Carballo M,et al.Lifestyle factors and oncogenic papillomavirus infection in a high-risk male population[J].PLoS One,2017,12(9):e0184492.
[5]Teixeira LO,Amaral SC,Finger-Jardim F,et al.Frequency of Human Papillomavirus in the placenta,in the colostrum and in the umbilical cord blood[J].Revista brasileira de ginecologia e obstetrícia:revista da Federac2o Brasileira das Sociedades de Ginecologia e Obstetrícia,2015,37(5):203-207.
[6]Sinclair KA,Woods CR.Venereal warts in children[J].Pediatrics in review/American Academy of Pediatrics,2011,32(3):115-121.
[7]Quint KD,de Koning MN,Quint WG.Progression of cervical low grade squamous intraepithelial lesions:in search of prognostic biomarkers[J].European journal of obstetrics,gynecology,and reproductive biology,2013,170(2):501-506.
[8]Chin-Hong PV,Vittinghoff E,Cranston RD,et al.Age-related prevalence of anal cancer precursors in homosexual men:the EX-PLORE study[J].Journal of the National Cancer Institute,2005,97(12):896-905.
[9]de Sanjose S,Quint WG,Alemany L,et al.Human papillomavirus genotype attribution in invasive cervical cancer:a retrospective cross-sectional worldwide study[J].The Lancet.Oncology,2010,11(11):1048-1056.
[10]Alemany L,Cubilla A,Halec G,et al.Role of Human Papillomavirus in Penile Carcinomas Worldwide[J].European urology,2016,69(5):953-961.
[11]Richardson H,Kelsall G,Tellier P,et al.The natural history of type-specific human papillomavirus infections in female university students[J].Cancer epidemiology,biomarkers&prevention:apublication of the American Association for Cancer Research,cosponsored by the American Society of Preventive Oncology,2003,12(6):485-490.
[12]王秀丽,徐世正,张春荣,等.δ-氨基酮戊酸光动力疗法治疗男性尿道尖锐湿疣[J].中国皮肤性病学杂志,2001,15(2):103-104.
[13]Du J,Lu XN,Li F,et al.Comparison between photodynamic therapy with topical application of 5-aminolevulinic acid and CO2laser therapy in the treatment of cervical condylomata acuminate:a randomized controlled trial[J].International journal of clinical and experimental,2015,8(7):11342-11346.
[14]Shi H,Zhang X,Ma C,et al.Clinical analysis of five methods used to treat condylomata acuminata[J].Dermatology(Basel,Switzerland),2013,227(4):338-345.
[15]王秀丽,姚红霞,缪飞,等.5-氨基酮戊酸光动力疗法治疗宫颈上皮内瘤样病变Ⅰ级[J].中华临床医师杂志(电子版),2011,5(16):4751-4755.
[16]Schiller JT,CastellsaguéX.A review of clinical trials of human papillomavirus prophylactic vaccines[J].Vaccine,2012,30Suppl(5):F123-138.
[17]Kann L,McManus T,Harris WA,et al.Youth Risk Behavior Surveillance-United States,2015[J].Morbidity and mortality weekly report.Surveillance summaries(Washington,D.C.:2002),2016,65(6):1-174.
[18]Schwarz T,Spaczynski M,Kaufmann A,et al.Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55years and first-time modelling of antibody responses in mature women:results from an open-label 6-year follow-up study[J].BJOG:an international journal of obstetrics and gynaecology,2015,122(1):107-118.
[19]CastellsaguéX,Mu1oz N,Pitisuttithum P,et al.End-of-study safety,immunogenicity,and efficacy of quadrivalent HPV(types 6,11,16,18)recombinant vaccine in adult women 24-45years of age[J].British journal of cancer,2011,105(1):28-37.
[20]Schwarz TF,Spaczynski M,Schneider A,et al.Immunogenicity and tolerability of an HPV-16/18AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55years[J].Vaccine,2009,27(4):581-587.
[21]Dobson SR,McNeil S,Dionne M,et al.Immunogenicity of 2doses of HPV vaccine in younger adolescents vs 3doses in young women:a randomized clinical trial[J].JAMA,2013,309(17):1793-1802.
[22]Petrosky E,Bocchini JA,Hariri S,et al.Use of 9-valent human papillomavirus(HPV)vaccine:updated HPV vaccination recommendations of the advisory committee on immunization practices[J].MMWR,2015,64(11):300-304.
[23]Th9ne K,Horn J.Evaluation of vaccination herd immunity effects for anogenital warts in a low coverage setting with human papillomavirus vaccine-an interrupted time series analysis from2005to 2010using health insurance data[J].BMC infectious diseases,2017,17(1):564.
[24]Garland SM,Ault KA,Gall SA,et al.Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18vaccine:a combined analysis of five randomized controlled trials[J].Obstetrics and gynecology,2009,114(6):1179-1188.
[25]Paavonen J,Naud P,Salmerón J,et al.Efficacy of human papillomavirus(HPV)-16/18AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types(PA-TRICIA):final analysis of a double-blind,randomised study in young women[J].Lancet,2009,374(9686):301-314.
[26]Bednarczyk RA,Davis R,Ault K,et al.Sexual activity-related outcomes after human papillomavirus vaccination of 11-to 12-year-olds[J].Pediatrics,2012,130(5):798-805.
[27]Ferris D,Samakoses R,Block SL,et al.Long-term study of a quadrivalent human papillomavirus vaccine[J].Pediatrics,2014,134(3):e657-665.
[28]Werner RN,Westfechtel L,Dressler C.Anogenital warts and other HPV-associated anogenital lesions in the HIV-positive patient:a systematic review and meta-analysis of the efficacy and safety of interventions assessed in controlled clinical trials[J].Sexually transmitted infections,2017,93(8):543-550.